000			02265nim a2200505 a 4500
001			HST8232
003			UkLoHST
006			m o h
007			cr nna||||||||
007			sr |mnnnnnzne|
008			210904s2021 enk|||||o||h||||||||eng d
028	5	0	_a8232 _bHenry Stewart Talks
035			_a(UkLoHST)4730
040			_aUkLoHST _beng _cUkLoHST
100	1		_aWherry, E. John. _4spk
245	1	0	_amRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals _h[electronic resource] / _can interview with E. John Wherry.
260			_aLondon : _bHenry Stewart Talks, _c2021.
300			_a1 online resource (1 streaming audio file (17 min.)).
490	1		_aInterviews on Covid-19, _x2056-452X
500			_aAudio interview.
500			_aTitle from title frames.
505	0		_aContents: Monitoring the levels of immune cells, e.g. memory B cells, rather than levels of antibodies, as an indication of long term immune protection -- The efficacy of vaccines in previously infected vs previously uninfected individuals -- The efficacy of a single vs double dose -- The potential value of administrating a "booster" that is different from the previous administered vaccine in an individual, AKA "mixing-and-matching".
506			_aAccess restricted to subscribers.
538			_aMode of access: World Wide Web.
650		0	_aCoronavirus infections _xVaccination.
650		0	_aCOVID-19 (Disease) _xResearch.
650		0	_aCOVID-19 (Disease) _xVaccination.
650		0	_aMessenger RNA.
650		0	_aVaccines.
650		2	_aAntibodies, Neutralizing _ximmunology.
650		2	_aAntibodies, Viral _ximmunology.
650		2	_aB-Lymphocytes _ximmunology.
650		2	_aCOVID-19 Vaccines _xadministration & dosage.
650		2	_aCOVID-19 _ximmunology.
650		2	_aCOVID-19 _xprevention & control.
650		2	_aImmunization, Secondary.
650		2	_amRNA Vaccine.
650		2	_aSARS-CoV-2 _ximmunology.
650		2	_aSpike Glycoprotein, Coronavirus _ximmunology.
650		2	_aVaccination.
650		2	_aVaccines, Synthetic.
830		0	_aHenry Stewart talks. _pBiomedical & life sciences collection. _pInterviews on Covid-19.
856	4	0	_uhttps://hstalks.com/bs/4730/
856	4	2	_uhttps://hstalks.com/bs/p/1060/ _3Series
999			_c75697 _d75697